Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

BACKGROUND: In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence suggests that a similar response rate may be obtained wi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mecenate, Fabrizio, Pellicelli, Adriano M, Barbaro, Giuseppe, Romano, Mario, Barlattani, Angelo, Mazzoni, Ettore, Bonaventura, Maria Elena, Nosotti, Lorenzo, Arcuri, Pasquale, Picardi, Antonio, Barbarini, Giorgio, D'Ambrosio, Cecilia, Paffetti, Amerigo, Andreoli, Arnaldo, Soccorsi, Fabrizio
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2010
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837223/
https://ncbi.nlm.nih.gov/pubmed/20170514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-10-21
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items